Email Updates

Search form

You are here

HVTN 107

Status
Ongoing
Phase
I/II
Objective

The purpose of this study is to evaluate the safety and immune response to an HIV clade C vaccine and to an MF59- or alum-adjuvanted clade C Env protein in healthy, HIV-uninfected adults.

Prevention Option(s)
HIV Vaccine
Study Design
Randomized
Arms and Assigned Interventions
Description
Active Comparator: Group 1: ALVAC-HIV + gp120/MF59 Participants will receive the ALVAC-HIV (vCP2438) vaccine in the left deltoid at months 0, 1, 3, 6, and 12, and Bivalent Subtype C gp120/MF59 in the right deltoid at months 3, 6, and 12.
Mode of Delivery
Intramuscular
Products
ALVAC
gp120
ARMs
Experimental
Clade
C
Description
Active Comparator: Group 2: ALVAC-HIV + gp120/Al(OH)3 Participants will receive the ALVAC-HIV (vCP2438) vaccine in the left deltoid at months 0, 1, 3, 6, and 12, and Bivalent Subtype C gp120 admixed with Al(OH)3 Suspension in the right deltoid at months 3, 6, and 12.
Mode of Delivery
Intramuscular
Products
ALVAC
gp120
ARMs
Experimental
Clade
C
Description
Active Comparator: Group 3: ALVAC-HIV + gp120/MF59 Participants will receive the ALVAC-HIV (vCP2438) vaccine in the left deltoid and Bivalent Subtype C gp120/MF59 in the right deltoid at months 0, 1, 6, and 12.
Mode of Delivery
Intramuscular
Products
ALVAC
gp120
ARMs
Experimental
Clade
C
Description
Active Comparator: Group 4: ALVAC-HIV + gp120 Participants will receive the ALVAC-HIV (vCP2438) vaccine in the left deltoid at months 0, 1, 3, 6, and 12, and Bivalent Subtype C gp120 in the right deltoid at months 3, 6, and 12.
Mode of Delivery
Intramuscular
Products
ALVAC
gp120
ARMs
Experimental
Clade
C
Trial Sponsors
NIAID
March 2017
May 2019
Enrollment
132
18
Years
40
Years
Population
Women
Men
Sites

Site(s) - Bara

Soweto
South Africa

Emavundleni (EMA) CRS

Cape Town
South Africa

The Aurum Institute, Tembisa Hospital

Tembisa
South Africa

eThekwini CRS

Durban, KwaZulu-Natal
South Africa

Site(s) - Maputo

Mozambique

Seke South Clinical Research Site

Harare
Zimbabwe